MENU
TENX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Tenax Therapeutics (TENX) Ownership - Who owns Tenax Therapeutics?

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension... Show more

A.I.Advisor
Nov 12, 2026

What Is Tenax Therapeutics (TENX)? Company Overview, Business Model and Market Position

Key Takeaways

  • TENX is the Nasdaq ticker for Tenax Therapeutics, Inc., a development-stage biopharmaceutical company focused on cardiopulmonary diseases.
  • The company is headquartered in Chapel Hill, North Carolina, and was formerly known as Oxygen Biotherapeutics before adopting its current name in 2014.
  • Its lead drug candidate is TNX-103, an oral formulation of levosimendan being developed for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
  • As a development-stage company, Tenax has no approved products or product revenue, and its business model depends on advancing clinical trials and securing future financing.
  • Because its value is tied closely to clinical trial outcomes, TENX carries a materially higher risk profile than established, revenue-generating pharmaceutical companies.

Introduction

Tenax Therapeutics, Inc. (TENX) is a small-cap biotechnology company developing therapies for cardiovascular and pulmonary diseases that currently have limited treatment options. Investors follow the stock primarily because of its lead pipeline program targeting a condition with no approved therapy in the United States, a dynamic that creates both substantial opportunity and substantial clinical risk.

Company Overview and Business Model

Tenax Therapeutics is a development-stage pharmaceutical company, meaning it does not yet generate revenue from product sales. Its business model centers on identifying, developing, and, if successful, commercializing drug candidates that address high-unmet-need conditions in the heart and lung space. The company traces its corporate roots to 1967 and was formerly named Oxygen Biotherapeutics, Inc. before changing its name to Tenax Therapeutics, Inc. in September 2014. It is headquartered in Chapel Hill, North Carolina.

The company's most advanced program is levosimendan, a drug it is developing in oral and intravenous formulations under the identifiers TNX-101, TNX-102, and TNX-103. Levosimendan is a calcium sensitizer and potassium-channel activator originally developed for intravenous use in patients with acutely decompensated heart failure. While the intravenous form has received marketing authorization in dozens of countries, it is not approved in the United States or Canada.

Tenax's lead candidate, TNX-103, is an oral formulation of levosimendan being studied for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). In heart failure with preserved ejection fraction (HFpEF), the heart's pumping strength is maintained, but the muscle is stiff and struggles to fill with blood properly; in PH-HFpEF, elevated pressure in the lung's blood vessels adds further strain. The company states that this is the most common form of pulmonary hypertension globally and that no product has been approved to treat it, representing a meaningful unmet medical need.

Beyond levosimendan, the company has also evaluated TNX-201, an oral formulation of imatinib, a type of drug known as a tyrosine kinase inhibitor, for pulmonary arterial hypertension (PAH). In practice, Tenax has prioritized levosimendan as its core near-term value driver.

Financial Profile and Development Stage

As a development-stage company, Tenax does not report product revenue and has historically generated net losses while funding research and development (R&D) and general operations. Its financial profile is typical of early-stage biotechnology firms: the company relies on equity financings, warrant exercises, and cash reserves to fund clinical trials. Advancing its Phase 3 program — the late-stage trials used to generate the safety and efficacy evidence regulators review before considering approval — requires meaningful ongoing capital. Investors evaluating TENX should focus on the company's cash position and projected runway alongside its clinical milestones, since future financing needs are an inherent part of its operating model.

Why Investors Follow TENX

Investor interest in TENX is driven largely by the size and nature of the opportunity its lead program targets. A therapy for PH-HFpEF would address a large, underserved patient population with no approved treatment options, a profile that could support meaningful commercial value if development is successful. The company's positioning is reinforced by levosimendan's long-established safety record from its international use, which Tenax cites as a de-risking factor for its reformulation approach.

More broadly, the stock appeals to investors seeking exposure to a focused, single-asset biotechnology story with a clear clinical catalyst. Because Tenax's near-term value is concentrated in one program, its profile differs sharply from diversified pharmaceutical companies with multiple revenue streams.

Risks and Important Considerations

Investing in Tenax Therapeutics carries several important risks. First, the company has no approved products or recurring revenue, and its future depends heavily on the success of its clinical trials and regulatory reviews, which are uncertain by nature. Clinical results, including the company's Phase 3 LEVEL trial of TNX-103, are a central driver of the stock's outlook, and unfavorable or mixed data can materially affect the company's prospects.

Second, Tenax faces significant competition and scientific risk in the broader heart-failure and pulmonary-hypertension space, where larger, better-funded companies are also developing treatments. Third, the company will likely require additional capital to complete development and potentially commercialize its candidates, which could result in share dilution for existing investors. Finally, as a small-cap biotech stock, TENX can exhibit high volatility, and its valuation may reflect clinical and regulatory expectations rather than established fundamentals. Prospective investors should consider their own risk tolerance and the speculative nature of development-stage biopharmaceutical investing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that align with their own investment strategies. Whether you are researching development-stage biotech names like TENX or comparing broader market opportunities, the AI Screener offers a structured way to refine your search and focus on the candidates that matter to you.

Conclusion

Tenax Therapeutics is a focused, development-stage biotechnology company pursuing a novel therapy for a large and currently untreated cardiopulmonary condition. Its concentrated, single-asset profile makes it distinctive within the healthcare sector, but that same concentration is also the source of its elevated risk. For investors, TENX represents a story defined by clinical execution and regulatory progress rather than near-term profitability — a profile best understood as a high-risk, high-uncertainty segment of the biotech market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
Medical Specialties
Address
101 Glen Lennox Drive
Phone
+1 919 855-2100
Employees
16
Web
https://www.tenaxthera.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
63.25M
P/E Ratio
-1.14
Total Cash
117.98M
Projected Growth
N/A
Total Debt
278.8K
Revenue
N/A
Risk (Beta)
-0.31
Dividend Yield
N/A
Total Cash/Share
3.15
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Who owns Tenax Therapeutics? TENX symbol Ownership - Tickeron.com